Teva Pharmaceutical Industries Ltd. and Antares Pharma, Inc., an Ewing, New Jersey-based pharmaceutical company, have launched the generic equivalent to GlaxoSmithKline’s Imitrex (sumatriptan succinate) injection, 4 mg and 6 mg single-dose, prefilled syringe autoinjectors, in the US. Sumatriptan injection is used to treat acute migraine with or without aura, and acute cluster headaches in adults. Sumatriptan injection is self-administered subcutaneously into the back of arm or outer thigh.

Sumatriptan injection had annual sales of approximately $183 million in the United States, according to IMS data as of March 2016, and as reported by Teva.

Source: Teva Pharmaceutical Industries